Skip to main content
Premium Trial:

Request an Annual Quote

Elsevier's SoftwareX

Elsevier has launched a new open access journal, SoftwareX, that's intended to provide a dedicated publishing home for articles on software and computational tools that impact the research process but traditionally would not be acknowledged or reported on systematically. With the launch of SoftwareX, researchers will have a forum where such applications can be systematically organized, curated, indexed, and shared through research databases. Journal articles will include summaries of where the software has already been used and its impact; and display  metadata such as the version, operating system, programming language, and the license under which the software is published. All software will be available within the journal's repository on github.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.